丙戊酸钠缓释制剂治疗小儿癫癎78例

目的 :观察丙戊酸钠缓释制剂 (德巴金 )治疗小儿癫的临床疗效。方法 :根据不同年龄选择丙戊酸钠缓释片 /糖浆治疗 78例癫患儿 ,并密切观察其发作控制的程度 ,嘱定期复查肝功能及血常规。结果 :完全控制 5 8例(74.4% ) ,显效 10例 (12 .8% ) ,有效 5例 (6.4% ) ,无效及效差 5例 (6.4% ) ,总有效率 93 .6%。结论 :丙戊酸钠缓释制剂是一种新型广谱抗癫药 ,使用方便 ,疗效显著 ,无明显的不良反应 ,是小儿癫的首选药物

Sodium Valproate in the Treatment of 78 Cases of Childhood Epilepsy

Objective: To observe the clinical effect of depakine (sodium valproate) in the treatment of childhood epilepsy. Methods:78 epileptic children were treated with either godilum valproate sustained-release tablets or syrups according to their ages, the control degree of the seizures were observed and reexamination of liver function and blood routine were carried at periodically. Results: Of the 78 cases, 58 cases (74.4 percent) were completely controlled, 10 cases (12.8 percent) significantly improved, 5 cases (6.4 percent) improved, 5 cases (6.4 percent) remained the same. The total effective rate was 93.6 percent. Conclusion: Depakine is a new broad-spectrum, easily used anti-epliepsy drug. Its efficacy is significant and there are different dosage forms to be selected and no significant adverse reactions. So depakine is the first selection in treating childhood epilepsy and suited for clinical application.